Treatment of dementia with lewy bodies

Current Treatment Options in Neurology

Volumn 15, Issue 6, 2013, Pages 738-764

  Boot, Brendon P ^a   McDade, Eric M ^b   McGinnis, Scott M ^a   Boeve, Bradley F ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Antipsychotic; Cholinesterase inhibitors; Dementia with Lewy bodies; Dysautonomia; Parkinson's disease dementia; REM sleep behavior disorder; Treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; DONEPEZIL; ESCITALOPRAM; FLUDROCORTISONE; GALANTAMINE; INDOMETACIN; ISPAGULA; LUBIPROSTONE; MACROGOL; MEMANTINE; MIDODRINE; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; QUETIAPINE; RIVASTIGMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TROSPIUM CHLORIDE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

ARTICLE; AUTONOMIC DYSFUNCTION; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DETRUSOR DYSSYNERGIA; DIFFUSE LEWY BODY DISEASE; DRUG INDICATION; ERECTILE DYSFUNCTION; HALLUCINATION; HUMAN; MOTOR DYSFUNCTION; NEUROPSYCHIATRY; ORTHOSTATIC HYPOTENSION; PATIENT EDUCATION; SEIZURE; SEXUAL DYSFUNCTION; SLEEP DISORDER; SYMPTOMATOLOGY;

EID: 84892366392     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-013-0261-6     Document Type: Article

References (117)

1. McKeith I et al. Dementia with Lewy bodies: diagnosis and management: third report of the DLB Consortium. Neurology. 2005;65: 1863-72.
2. McKeith IG et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54(5): 1050-8.
3. Rahkonen T et al. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry. 2003;74:720-4.
4. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34(6):561-6.
5. Boeve B. Diagnosis and management of non Alzheimer dementias. In: Noseworthy JW, editor. Neurological therapeutics: principles and practice. 2005.
6. McKeith IG et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113-24.
7. Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2013:1-11.
8. Nelson PT et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol. 2010;257(3):359-66.
9. Boot B. Letter to the Editor the incidence and prevalence of dementia with Lewy bodies is underestimated. Psychol Med. 2013:1-2.
10. Ferman TJ et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011;77(9):875-82.
11. Boeve BF, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013.
12. Ferman TJ et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004;62(2):181-7.
13. Lim SM et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50(10):1638-45.
14. Walker Z et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004;62(9):1568-72.
15. Walker Z et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176-81.
16. Treglia G et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22(1):43-55.
17. Treglia G, et al. Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques? J Neuroimaging. 2012.
18. Jellinger KA. Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med. 2012;16(6):1166-83.
19. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution - a pilot study. Acta Neuropathol. 2003;106(3):191-201.
20. Uchikado H et al. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006;65(7):685-97.
21. Schneider JA et al. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 2009;18(3):691-701.
22. Ballard C et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatr. 1999;156(7):1039-45.
23. Ballard C et al. Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol. 2001;58:977-82.
24. McKeith I et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031-6.
25. Aarsland D, Mosimann UP, McKeith IG Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17(3):164-71.
26. Samuel W et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000;15(9):794-802.
27. Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41-52.
28. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev. 2003;3, CD003672.
29. Levy R et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet. 1994;343(8890):176.
30. Klein JC et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74(11):885-92.
31. Rolinski M et al. Cholinesterase inhibitors for dementia with Lewy bodies. Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012;3, CD006504.
32. Aarsland D et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72(6):708-12.
33. Emre M et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509-18.
34. Ravina B et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76(7):934-9.
35. Emre M et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969-77.
36. Aarsland D et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8:613-8.
37. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10-6.
38. Thomas A et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400-4.
39. Boot BP et al. Risk factors for dementia with Lewy bodies: a case-control study. Neurology. 2013;81(9):833-40.
40. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577-85.
41. Banerjee S et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403-11.
42. Weintraub D et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord. 2005;20(9):1161-9.
43. Chung TH et al. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord. 2003;10(2):59-65.
44. Seppi K et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3:S42-80.
45. Slaughter JR et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2001;13(2):187-96.
46. Lemke MR. Depressive symptoms in Parkinson's disease. Eur J Neurol. 2008;15 Suppl 1:21-5.
47. Takahashi S et al. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009;9(2):56-61.
48. Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci. 2008;266(1-2):216-28.
49. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology. 1996;47(5):1148-52.
50. Ferman TJ et al. The phenomenology of psychotic features in dementia with Lewy bodies (DLB) and Alheimer's diesease (AD). Neurology. 2005;64:A257.
51. Wood LD et al. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. Am J Geriatr Pharmacother. 2010;8(4):294-315.
52. Kurlan R et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356-63.
53. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatr. 2006;14(3):191-210.
54. Schneider L et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525-38.
55. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006;7(6):492-500.
56. Rochon PA et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168(10):1090-6.
57. Musicco M et al. Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease. Dement Geriatr Cogn Disord. 2011;31(3):218-24.
58. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-43.
59. Lopez O, et al. The long-term effects of typical and atypical antipsychotics in patients with Probable Alzheimer's disease. Am J Psychiatry. (in press).
60. Aarsland D et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633-7.
61. Ballard C et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet. 1998;351(9108):1032-3.
62. McKeith I et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673-8.
63. Rochon PA et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165(16):1882-8.
64. Hassan I. Consultation-liaison psychiatry and prevention of severe neuroleptic sensitivity reactions in dementia with Lewy bodies. Australas Psychiatry. 2011;19(6):536-7.
65. Johnell K, Religa D, Eriksdotter M. Differences in drug therapy between dementia disorders in the Swedish Dementia Registry: a nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord. 2013;35:239-48.
66. Ballard C et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-7.
67. Frieling H et al. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17(3):165-71.
68. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000;15(2):201-11.
69. Schneider F et al. Psychiatric symptoms in Parkinson's disease. Eur Arch Psychiatry Clin Neurosci. 2008;258 Suppl 5:55-9.
70. Fernandez HH et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003;18(5):510-4.
71. Factor SA et al. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12-week open-label extension in the PSYCLOPS trial. Mov Disord. 2001;16(1):135-9.
72. Klein C et al. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol. 2003;26(1):8-11.
73. Pollak P et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689-95.
74. Morgante L et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27(4):153-6.
75. Merims D et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol. 2006;29(6):331-7.
76. Husebo BS, Ballard C, Aarsland D. Pain treatment of agitation in patients with dementia: a systematic review. Int J Geriatr Psychiatry. 26(10):1012-8.
77. Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol A Biol Sci Med Sci. 2007;62(8):908-16.
78. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 169(9):946-53.
79. Rhodes-Kropf J et al. Managing the patient with dementia in long-term care. Clin Geriatr Med. 2011;27(2):135-52.
80. Ballard C et al. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). Am J Geriatr Psychiatr. 2009;17(9):726-33.
81. Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20(2):293-308.
82. Hicks SW et al. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism Relat Disord. 2011;17(5):379-81.
83. Hasnain M et al. Pharmacological management of psychosis in elderly patients with parkinsonism. Am J Med. 2009;122(7):614-22.
84. Molloy S et al. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76(9):1200-3.
85. Lucetti C et al. Levodopa response in dementia with lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010;16(8):522-6.
86. Lawrence J, Parmenter T, McDonald T. Failure to manage constipation in Parkinson's disease. A review of medical services a patients perspective. Mov Disord. 2013;28 Suppl 1:187.
87. Jost WH. Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management. Drugs Aging. 1997;10(4):249-58.
88. Ashraf W et al. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord. 1997;12(6):946-51.
89. Zangaglia R et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord. 2007;22(9):1239-44.
90. Ondo WG et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78(21):1650-4.
91. Thaisetthawatkul P et al. Autonomic dysfunction in dementia with Lewy bodies. Neurology. 2004;62(10):1804-9.
92. Hishikawa N et al. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (Berl). 2003;105:341-50.
93. Schoffer KL et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord. 2007;22(11):1543-9.
94. Sakakibara R et al. Lower urinary tract function in dementia of Lewy body type. J Neurol Neurosurg Psychiatry. 2005;76(5):729-32.
95. Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2007;13(6):323-32.
96. Kay GG et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195-201.
97. Pagoria D, O'Connor RC, Guralnick ML. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep. 2011;12(5):351-7.
98. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41(6):636-44.
99. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord. 2000;15(2):305-8.
100. Hussain IF et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001;71(3):371-4.
101. Hassan A et al. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord. 2011;17(4):260-4.
102. Malhotra R, Avidan AY. Neurodegenerative disease and REM behavior disorder. Curr Treat Options Neurol. 2012;14(5):474-92.
103. Hogl B et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905-9.
104. Kuntz K, et al. Safety, tolerability, and efficacy of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies. Neurology. 2012;(78):P04.192.
105. Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7(6):639-44.
106. Boeve B, Silber M, Ferman T. Melatonin for treatment of REM sleep behavior disorderin neurologic disorders: results in 14 patients. Sleep Med. 2003;4:281-4.
107. Dowling GA et al. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med. 2005;6(5):459-66.
108. Medeiros CA et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007;254(4):459-64.
109. Mace N, Rabins P. The 36-hour day: a family guide to caring for persons with Alzheimer disease, related dementing illnesses, and memory loss in later life. 5th ed. Baltimore: JHUP; 2011.
110. Chenoweth L et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol. 2009;8(4):317-25.
111. Moyle W et al. The effect of massage on agitated behaviours in older people with dementia: a literature review. J Clin Nurs. 2013;22(5-6):601-10.
112. Holliday-Welsh DM, Gessert CE, Renier CM. Massage in the management of agitation in nursing home residents with cognitive impairment. Geriatr Nurs. 2009;30(2):108-17.
113. Ueda T et al. Effects of music therapy on behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. Ageing Res Rev. 2013;12(2):628-41.
114. Raglio A et al. Music, music therapy and dementia: a review of literature and the recommendations of the Italian Psychogeriatric Association. Maturitas. 2012;72(4):305-10.
115. Iranzo A et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2010;9(11):1070-7.
116. McDade EM, Boot BP, Christianson TJ, Pankratz VS, Boeve BF, Ferman TJ, et al. Subtle gait changes in patients with REM sleep behavior disorder. Mov Disord. 2013. doi:10.1002/mds.25653.
117. Boeve B. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:17-56.